Prelude Therapeutics Incorporated

NASDAQ:PRLD

Biotechnology

Healthcare
$3.30 -3.22%

-$0.14 today

Market cap
$191.00M
Beta
1.01
P/E (TTM)
-4.5
EPS (TTM)
-$0.94
52W Low $0.75High $5.54

Volume 0.23M

Average 0.38M

PRLD Weighted Avg Shares (Diluted)

Average shares outstanding including dilutive securities, used to calculate diluted EPS.

Prelude Therapeutics IncorporatedNASDAQ: PRLD

Weighted Avg Shares (Diluted) · Q1 FY2026 · quarter ended Mar 2026

Weighted avg shares (diluted) growth accelerates

Q1 FY2026 weighted avg shares (diluted) of 82.52M shares rose 8.6% year over year, ahead of the -1.9% change in trailing-twelve-month weighted avg shares (diluted). Sequentially, it rose 31.1% from the prior quarter. Over 3 fiscal years it compounded at +17.6% a year.

Context

  • Weighted avg shares (diluted) increased in 3 of the last 3 fiscal years.
  • FY2025 was the highest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly growth of +8.6% holds above the trailing-twelve-month pace of -1.9%.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterMar 2026
82.52M+31.1% QoQ
Last fiscal yearDec 2025
76.96M+1.5% YoY
LTMMar 2026
74.4M-1.9% YoY
Weighted Avg Shares (Diluted) past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+8.6%——
1 year+1.5%——
3-year CAGR+17.6%——
5-year CAGR——
10-year CAGR——

Weighted Avg Shares (Diluted) history

Shares · from the income statement

Latest · FY2025
76.96M USD
Year-over-year change
+1.5%
4-year CAGR
+12.8%

Weighted Avg Shares (Diluted) vs competitors

How PRLD compares with its peers on the latest reported figures

  • PRLD's LTM Mar 2026 weighted avg shares (diluted) of 74.4M shares is the 4th highest of the 11 companies compared; the peer median is 53.95M shares.
  • Its year-over-year change of -1.9% is the lowest of 11, against a peer median of +17.6%.
  • Over three fiscal years its annual growth of +17.6% compares with a peer median of +21.0%.
PRLD Competitors Peer median
Weighted Avg Shares (Diluted) for PRLD and competitors
Company Period LTM YoY 3-year CAGR
IVAInventiva S.A.FY2025186.8M +259.4%+65.2%
TNYATenaya Therapeutics, Inc.LTM Mar 2026158.02M +71.7%+50.6%
CRBUCaribou Biosciences, Inc.LTM Mar 202694.18M +3.6%+15.4%
PRLDPrelude Therapeutics IncorporatedLTM Mar 202674.4M -1.9%+17.6%
FHTXFoghorn Therapeutics Inc.LTM Mar 202664.63M +7.9%+14.8%
PYXSPyxis Oncology, Inc.LTM Mar 202662.52M +2.9%+23.4%
EPRXEupraxia Pharmaceuticals Inc.LTM Mar 202645.37M +27.3%+27.5%
IMRXImmuneering CorporationLTM Mar 202640.92M +29.8%+18.6%
OBIOOrchestra BioMed Holdings, Inc.LTM Mar 202638.39M +2.6%+14.7%
ENTAEnanta Pharmaceuticals, Inc.LTM Mar 202621.37M +0.6%+1.2%
AVTXAvalo Therapeutics, Inc.LTM Mar 202615.86M +60.9%+599.3%
Peer median (excluding PRLD) 53.95M+17.6%+21.0%

Competitors are the stored peer set for PRLD. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue0007M12.14M
Cost of Revenue00001.71M
Gross Profit0007M10.43M
Gross Margin———100.0%85.9%
Research & Development86.78M92.89M103.39M118M94.3M
Selling, General & Admin26.96M30.65M28.88M28.72M22.41M
Operating Expenses113.74M123.54M132.28M146.71M115M
Depreciation & Amortization915K1.32M1.17M1.77M1.71M
EBITDA(110.78M)(114.11M)(120.66M)(125.4M)(97.79M)
EBITDA Margin———-1791.4%-805.5%
Operating Income(113.74M)(123.54M)(132.28M)(139.71M)(104.57M)
Operating Margin———-1995.9%-861.3%
Interest Income00000
Interest Expense00000
Other Income / Expenses2.04M8.1M10.44M12.54M5.07M
Income Before Tax(111.69M)(115.44M)(121.83M)(127.17M)(99.5M)
Pre-Tax Margin———-1816.8%-819.6%
Income Tax Expense00000
Net Income(111.69M)(115.44M)(121.83M)(127.17M)(99.5M)
Net Margin———-1816.8%-819.6%
EPS (Basic)(2.33)(2.27)(2.02)(1.68)(1.29)
EPS (Diluted)(2.33)(2.27)(2.02)(1.68)(1.29)
Weighted Avg Shares47.6M47.37M60.36M75.81M76.96M
Weighted Avg Shares (Diluted)47.6M47.37M60.36M75.81M76.96M

Prelude Therapeutics Incorporated

NASDAQ:PRLD

Intrinsic Alpha fair value

Locked

Current Price

$3.30

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.